Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology

Stem Cells

Volumn 33, Issue 10, 2015, Pages 2887-2892

  Laplane, Lucie ^a,b,c,d   Beke, Allan ^a,b,c   Vainchenker, William ^a,b,c   Solary, Eric ^a,b,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Universite Paris Sud   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d Universite Paris 2   (France)

Author keywords

Cancer; Clonal evolution; Genetic predisposition; Induced pluripotent stem cells

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; JANUS KINASE 2 INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX1;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER GROWTH; CANCER MODEL; CANCER RESEARCH; CANCER STEM CELL; CANCER SUSCEPTIBILITY; CELL CULTURE; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL TRANSFORMATION; DRUG CYTOTOXICITY; DRUG SCREENING; GENE DOSAGE; GENETIC PREDISPOSITION; GENOMIC INSTABILITY; GERMLINE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; MALIGNANT TRANSFORMATION; MEDULLOBLASTOMA; MEGAKARYOPOIESIS; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE DISORDER; NEURAL STEM CELL; NONHUMAN; ONCOLOGY; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PHENOTYPE; PLURIPOTENT STEM CELL; SOMATIC CELL; THROMBOCYTOPENIA; TRANSFORMED CELL; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; GENETICS; INDUCED PLURIPOTENT STEM CELL; NEOPLASM; NUCLEAR REPROGRAMMING;

CELL TRANSFORMATION, NEOPLASTIC; CELLULAR REPROGRAMMING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NEOPLASMS;

EID: 84942364632     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2099     Document Type: Article

References (51)

1. Takahashi K, Yamanaka S,. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
2. Takahashi K, Tanabe K, Ohnuki M, et al., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
3. Connelly JP, Kwon EM, Gao Y, et al., Targeted correction of runx1 mutation in fpd patient-specific induced pluripotent stem cells rescues megakaryopoietic defects. Blood 2014; 124: 1926-1930.
4. Sakurai M, Kunimoto H, Watanabe N, et al., Impaired hematopoietic differentiation of runx1-mutated induced pluripotent stem cells derived from fpd/aml patients. Leukemia 2014; 28: 2344-2354.
5. Antony-Debré I, Manchev VT, Balayn N, et al., Level of runx1 activity is critical for leukemic predisposition but not for thrombocytopenia. Blood 2015; 125: 930-940.
6. Adamo A, Atashpaz S, Germain PL, et al., 7q11.23 dosage-dependent dysregulation in human pluripotent stem cells affects transcriptional programs in disease-relevant lineages. Nat Genet 2015; 47: 132-141.
7. Parmar K, D'Andrea A, Niedernhofer LJ,. Mouse models of fanconi anemia. Mutat Res 2009; 668: 133-140.
8. Liu GH, Suzuki K, Li M, et al., Modelling fanconi anemia pathogenesis and therapeutics using integration-free patient-derived ipscs. Nat Commun 2014; 5: 4330.
9. Chou ST, Byrska-Bishop M, Tober JM, et al., Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc Natl Acad Sci USA 2012; 109: 17573-17578.
10. Konishi H, Mohseni M, Tamaki A, et al., Mutation of a single allele of the cancer susceptibility gene brca1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci USA 2011; 108: 17773-17778.
11. Soyombo AA, Wu Y, Kolski L, et al., Analysis of induced pluripotent stem cells from a brca1 mutant family. Stem Cell Reports 2013; 1: 336-349.
12. Kim J, Hoffman John P, Alpaugh RK, et al., An ipsc line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Reports 2013; 3: 2088-2099.
13. Carette JE, Pruszak J, Varadarajan M, et al., Generation of iPSCs from cultured human malignant cells. Blood 2010; 115: 4039-4042.
14. Kumano K, Arai S, Hosoi M, et al., Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 2012; 119: 6234-6242.
15. Bedel A, Pasquet JM, Lippert E, et al., Variable behavior of ipscs derived from cml patients for response to tki and hematopoietic differentiation. PLoS One 2013; 8: e71596.
16. Gandre-Babbe S, Paluru P, Aribeana C, et al., Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood 2013; 121: 4925-4929.
17. Saliba J, Hamidi S, Lenglet G, et al., Heterozygous and homozygous jak2(v617f) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. PLoS One 2013; 8: e74257.
18. Ye Z, Liu CF, Lanikova L, et al., Differential sensitivity to jak inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. Stem Cells 2014; 32: 269-278.
19. Kreso A, Dick JE,. Evolution of the cancer stem cell model. Cell Stem Cell 2014; 14: 275-291.
20. Laplane L,. Identifying some theories in developmental biology: The case of the cancer stem cell theory. In:, Minelli A, Pradeu T, eds. Toward a Theory of Development. Oxford: Oxford University Press, 2014: 246-259.
21. Oshima N, Yamada Y, Nagayama S, et al., Induction of cancer stem cell properties in colon cancer cells by defined factors. PLoS One 2014; 9: e101735.
22. Kelly PN, Dakic A, Adams JM, et al., Tumor growth need not be driven by rare cancer stem cells. Science 2007; 317: 337.
23. Vermeulen L, de Sousa e Melo F, Richel DJ, et al., The developing cancer stem-cell model: Clinical challenges and opportunities. Lancet Oncol 2012; 13: e83-89.
24. Marjanovic ND, Weinberg RA, Chaffer CL,. Cell plasticity and heterogeneity in cancer. Clin Chem 2013; 59: 168-179.
25. Menendez JA, Joven J, Cufi S, et al., The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells. Cell Cycle 2013; 12: 1166-1179.
26. Friedmann-Morvinski D, Verma IM,. Dedifferentiation and reprogramming: Origins of cancer stem cells. EMBO Rep 2014; 15: 244-253.
27. Nishi M, Sakai Y, Akutsu H, et al., Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene 2014; 33: 643-652.
28. Nishi M, Akutsu H, Kudoh A, et al., Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell. Oncotarget 2014; 5: 8665-8680.
29. Chen L, Kasai T, Li Y, et al., A model of cancer stem cells derived from mouse induced pluripotent stem cells. PLoS One 2012; 7: e33544.
30. Scaffidi P, Misteli T,. In vitro generation of human cells with cancer stem cell properties. Nat Cell Biol 2011; 13: 1051-1061.
31. Hong D, Gupta R, Ancliff P, et al., Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008; 319: 336-339.
32. Greaves M,. Does everyone develop covert cancer? Nat Rev Cancer 2014; 14: 209-210.
33. Busque L, Patel JP, Figueroa ME, et al., Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012; 44: 1179-1181.
34. Welch JS, Ley TJ, Link DC, et al., The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-278.
35. Shlush LI, Zandi S, Mitchell A, et al., Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-333.
36. Corces-Zimmerman MR, Hong WJ, Weissman IL, et al., Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA 2014; 111: 2548-2553.
37. Genovese G, Kahler AK, Handsaker RE, et al., Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-2487.
38. Jaiswal S, Fontanillas P, Flannick J, et al., Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488-2498.
39. Vasanthakumar A, Godley LA,. On the origin of leukemic species. Cell Stem Cell 2014; 14: 421-422.
40. Hay M, Thomas DW, Craighead JL, et al., Clinical development success rates for investigational drugs. Nat Biotechnol 2014; 32: 40-51.
41. Bellin M, Marchetto MC, Gage FH, et al., Induced pluripotent stem cells: The new patient? Nat Rev Mol Cell Biol 2012; 13: 713-726.
42. Laurent LC, Nievergelt CM, Lynch C, et al., Restricted ethnic diversity in human embryonic stem cell lines. Nat Methods 2010; 7: 6-7.
43. Matsa E, Rajamohan D, Dick E, et al., Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 2011; 32: 952-962.
44. Braam SR, Tertoolen L, Casini S, et al., Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes. Stem Cell Res 2013; 10: 48-56.
45. Sullivan GJ, Hay DC, Park IH, et al., Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 2010; 51: 329-335.
46. Doege CA, Inoue K, Yamashita T, et al., Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature 2012; 488: 652-655.
47. Zhang X, Cruz FD, Terry M, et al., Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 2013; 32: 2249-2260.
48. Miyoshi N, Ishii H, Nagai K, et al., Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci USA 2010; 107: 40-45.
49. Gori JL, Butler JM, Chan YY, et al., Vascular niche promotes hematopoietic multipotent progenitor formation from pluripotent stem cells. J Clin Invest 2015; 125: 1243-1254.
50. Xia Y, Sancho-Martinez I, Nivet E, et al., The generation of kidney organoids by differentiation of human pluripotent cells to ureteric bud progenitor-like cells. Nat Protoc 2014; 9: 2693-2704.
51. Luni C, Serena E, Elvassore N,. Human-on-chip for therapy development and fundamental science. Curr Opin Biotechnol 2014; 25: 45-50.